Burger King hasn't publicly acknowledged this significant change yet, and its not known how or if the chicken is any different on the new sandwiches.
Analyst Ming-Chi Kuo predicts Apple will raise iPhone 14 costs, possibly increasing the base model’s price to nearly $1,000
Lotte Chilsung is expanding its business and adding vegan drink options through partnerships with startups.
Apple is expected to produce less than 1.5 million units of its first mixed reality headset that could enter the market in early 2023
Microsoft says making Activision Blizzard games exclusive to Xbox will not be profitable in response to Sony’s criticisms of the $68.7 billion acquisition
To commemorate Lamborghini's founding year of 1963, the fourth NFT will only be produced in a restricted quantity of 63 pieces.
HiteJinro has yet to reach a settlement with its unionized drivers even after five months into the conflict.
Defiance mounts as the EU sends increasingly mixed signals on accountability for rule of law foibles
Samsung wants to provide clients with a variety of services through these NFTs, including rewards like offline discounts at partner retailers.
Puma and Coca-Cola are collaborating to celebrate their long heritage through a nostalgic collection.
Korea’s CJ Cheiljedang to buy Dutch firm Batavia Biosciences for $226M
CJ Cheiljedang, South Korea’s largest food and beverage conglomerate, is set to buy Batavia Biosciences, a Dutch bio firm for $226 million or about €195 million. It was reported that the deal came not long after the company revealed its $8.5 billion growth plan for its four major business areas.
CJ Cheiljedang which is a subsidiary of CJ Group announced on Monday, Nov. 8, that it will be acquiring the said Dutch biotech company as part of its plan to broaden its presence in the contract biopharmaceutical production market.
According to The Korea Economic Daily, the company’s board of directors already gave the “go” signal for the acquisition of 75.8% share in Batavia Biosciences. It was reportedly posted in the regulatory filing that this deal is worth ₩267.7 billion or $226 million.
Moreover, CJ Cheiljedang shared it will buy 50,807 shares in the Leiden, Netherlands-headquartered biotech firm and this includes 13,007 new shares at €3,844 per share. It should be noted that the companies’ acquisition deal is still subject to approval by regulatory authorities in South Korea and the Netherlands.
Once the transactions are complete, CJ will immediately work on the expansion of its “red bio” business which refers to the line of work in the medical and pharmaceutical fields. “There’s no dominant leader in the gene therapy treatment market,” an official at CJ said in a statement. “We want to grow big in this area as soon as possible.”
Batavia Biosciences is based in the Netherlands but is has research and development (R&D) centers and sales offices in Hong Kong and Boston, U.S.A. It was founded by the researchers of Janssen Pharmaceuticals in 2010 and mainly worked on cell and gene therapies under CDMO or Contract Development and Manufacturing Organization program. It has extensive experience in virus vaccine, viral vector, monoclonal antibody, microbial vaccine, and recombinant protein development.
Finally, BioPharma reported that with its acquisition of Batavia Biosciences, it appears that CJ Group is directing its attention back to its pharmaceutical business. After unloading its healthcare unit to Kolmar Korea in 2018, CJ seems to have revived its interest in expanding in the biopharma line.